Biomatters taps Ammundsen as CEO

New Zealand-based Biomatters has a new CEO to lead the company amid a push to grow the organization's footprint in the U.S. market, where the provider of genomic research software called Geneious set up offices in Newark, NJ, and San Francisco last year. The company named Brett Ammundsen, a former managing director, as its chief executive. "There is a lot of excitement about the $1,000 genome, but sequencing entire genomes at a low cost generates an enormous amount of data, which requires expert interpretation," Ammundsen said in a statement. "To truly realize the promise of genomics, we need smart interfaces, allowing clinicians and consumers to connect to the knowledge associated with the genomic data and make real-world decisions with confidence." Release


Suggested Articles

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.

The $58 million financing round represents biopharma industry's growing interest in genomics data.